261 related articles for article (PubMed ID: 25359765)
1. Inhibition of histone H3K79 methylation selectively inhibits proliferation, self-renewal and metastatic potential of breast cancer.
Zhang L; Deng L; Chen F; Yao Y; Wu B; Wei L; Mo Q; Song Y
Oncotarget; 2014 Nov; 5(21):10665-77. PubMed ID: 25359765
[TBL] [Abstract][Full Text] [Related]
2. Silencing or inhibition of H3K79 methyltransferase DOT1L induces cell cycle arrest by epigenetically modulating c-Myc expression in colorectal cancer.
Yang L; Lei Q; Li L; Yang J; Dong Z; Cui H
Clin Epigenetics; 2019 Dec; 11(1):199. PubMed ID: 31888761
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
[TBL] [Abstract][Full Text] [Related]
4. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia.
Rau RE; Rodriguez BA; Luo M; Jeong M; Rosen A; Rogers JH; Campbell CT; Daigle SR; Deng L; Song Y; Sweet S; Chevassut T; Andreeff M; Kornblau SM; Li W; Goodell MA
Blood; 2016 Aug; 128(7):971-81. PubMed ID: 27335278
[TBL] [Abstract][Full Text] [Related]
5. Deficiency of H3K79 histone methyltransferase Dot1-like protein (DOT1L) inhibits cell proliferation.
Kim W; Kim R; Park G; Park JW; Kim JE
J Biol Chem; 2012 Feb; 287(8):5588-99. PubMed ID: 22190683
[TBL] [Abstract][Full Text] [Related]
6. Regulation of Wnt signaling target gene expression by the histone methyltransferase DOT1L.
Gibbons GS; Owens SR; Fearon ER; Nikolovska-Coleska Z
ACS Chem Biol; 2015 Jan; 10(1):109-14. PubMed ID: 25361163
[TBL] [Abstract][Full Text] [Related]
7. DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy.
Liu W; Deng L; Song Y; Redell M
PLoS One; 2014; 9(5):e98270. PubMed ID: 24858818
[TBL] [Abstract][Full Text] [Related]
8. The PZP Domain of AF10 Senses Unmodified H3K27 to Regulate DOT1L-Mediated Methylation of H3K79.
Chen S; Yang Z; Wilkinson AW; Deshpande AJ; Sidoli S; Krajewski K; Strahl BD; Garcia BA; Armstrong SA; Patel DJ; Gozani O
Mol Cell; 2015 Oct; 60(2):319-27. PubMed ID: 26439302
[TBL] [Abstract][Full Text] [Related]
9. Dot1L mediated histone H3 lysine79 methylation is essential to meiosis progression in mouse oocytes.
Wang X; Gao W; Ma X; Wang X; Song C; Huang X; Liu H
Neuro Endocrinol Lett; 2014; 35(6):523-30. PubMed ID: 25433842
[TBL] [Abstract][Full Text] [Related]
10. A medicinal chemistry perspective for targeting histone H3 lysine-79 methyltransferase DOT1L.
Anglin JL; Song Y
J Med Chem; 2013 Nov; 56(22):8972-83. PubMed ID: 23879463
[TBL] [Abstract][Full Text] [Related]
11. The histone methyltransferase Dot1/DOT1L as a critical regulator of the cell cycle.
Kim W; Choi M; Kim JE
Cell Cycle; 2014; 13(5):726-38. PubMed ID: 24526115
[TBL] [Abstract][Full Text] [Related]
12. The Histone Methyltransferase DOT1L Promotes Neuroblastoma by Regulating Gene Transcription.
Wong M; Tee AEL; Milazzo G; Bell JL; Poulos RC; Atmadibrata B; Sun Y; Jing D; Ho N; Ling D; Liu PY; Zhang XD; Hüttelmaier S; Wong JWH; Wang J; Polly P; Perini G; Scarlett CJ; Liu T
Cancer Res; 2017 May; 77(9):2522-2533. PubMed ID: 28209620
[TBL] [Abstract][Full Text] [Related]
13. Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.
Deshpande AJ; Chen L; Fazio M; Sinha AU; Bernt KM; Banka D; Dias S; Chang J; Olhava EJ; Daigle SR; Richon VM; Pollock RM; Armstrong SA
Blood; 2013 Mar; 121(13):2533-41. PubMed ID: 23361907
[TBL] [Abstract][Full Text] [Related]
14. Histone lysine methyltransferase SUV39H1 is a potent target for epigenetic therapy of hepatocellular carcinoma.
Chiba T; Saito T; Yuki K; Zen Y; Koide S; Kanogawa N; Motoyama T; Ogasawara S; Suzuki E; Ooka Y; Tawada A; Otsuka M; Miyazaki M; Iwama A; Yokosuka O
Int J Cancer; 2015 Jan; 136(2):289-98. PubMed ID: 24844570
[TBL] [Abstract][Full Text] [Related]
15. The histone H3K79 methyltransferase Dot1L is essential for mammalian development and heterochromatin structure.
Jones B; Su H; Bhat A; Lei H; Bajko J; Hevi S; Baltus GA; Kadam S; Zhai H; Valdez R; Gonzalo S; Zhang Y; Li E; Chen T
PLoS Genet; 2008 Sep; 4(9):e1000190. PubMed ID: 18787701
[TBL] [Abstract][Full Text] [Related]
16. SET7/9 inhibits oncogenic activities through regulation of Gli-1 expression in breast cancer.
Song Y; Zhang J; Tian T; Fu X; Wang W; Li S; Shi T; Suo A; Ruan Z; Guo H; Yao Y
Tumour Biol; 2016 Jul; 37(7):9311-22. PubMed ID: 26779630
[TBL] [Abstract][Full Text] [Related]
17. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.
Daigle SR; Olhava EJ; Therkelsen CA; Majer CR; Sneeringer CJ; Song J; Johnston LD; Scott MP; Smith JJ; Xiao Y; Jin L; Kuntz KW; Chesworth R; Moyer MP; Bernt KM; Tseng JC; Kung AL; Armstrong SA; Copeland RA; Richon VM; Pollock RM
Cancer Cell; 2011 Jul; 20(1):53-65. PubMed ID: 21741596
[TBL] [Abstract][Full Text] [Related]
18. DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells.
Steger DJ; Lefterova MI; Ying L; Stonestrom AJ; Schupp M; Zhuo D; Vakoc AL; Kim JE; Chen J; Lazar MA; Blobel GA; Vakoc CR
Mol Cell Biol; 2008 Apr; 28(8):2825-39. PubMed ID: 18285465
[TBL] [Abstract][Full Text] [Related]
19. DOT1L-mediated H3K79 methylation in chromatin is dispensable for Wnt pathway-specific and other intestinal epithelial functions.
Ho LL; Sinha A; Verzi M; Bernt KM; Armstrong SA; Shivdasani RA
Mol Cell Biol; 2013 May; 33(9):1735-45. PubMed ID: 23428873
[TBL] [Abstract][Full Text] [Related]
20. The upstreams and downstreams of H3K79 methylation by DOT1L.
Vlaming H; van Leeuwen F
Chromosoma; 2016 Sep; 125(4):593-605. PubMed ID: 26728620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
